OBJECTIVE: To compare the rates of gestational diabetes among women who received serial doses of 17-alpha hydroxyprogesterone caproate vs placebo. STUDY DESIGN: Secondary analysis of 2 double-blind randomized placebo-controlled trials of 17-alpha hydroxyprogesterone caproate given to women at risk for preterm delivery. The incidence of gestational diabetes was compared between women who received 17-alpha hydroxyprogesterone caproate or placebo. RESULTS: We included 1094 women; 441 had singleton and 653 had twin gestations. Combining the 2 studies, 616 received 17-alpha hydroxyprogesterone caproate and 478 received placebo. Among singleton and twin pregnancies, rates of gestational diabetes were similar in women receiving 17-alpha hydroxyprogesterone caproate vs placebo (5.8% vs 4.7%; P = .64 and 7.4% vs 7.6%; P = .94, respectively). In the multivariable model, progesterone was not associated with gestational diabetes (adjusted odds ratio, 1.04; 95% confidence interval, 0.62-1.73). CONCLUSION: Weekly administration of 17-alpha hydroxyprogesterone caproate is not associated with higher rates of gestational diabetes in either singleton or twin pregnancies.
RCT Entities:
OBJECTIVE: To compare the rates of gestational diabetes among women who received serial doses of 17-alpha hydroxyprogesterone caproate vs placebo. STUDY DESIGN: Secondary analysis of 2 double-blind randomized placebo-controlled trials of 17-alpha hydroxyprogesterone caproate given to women at risk for preterm delivery. The incidence of gestational diabetes was compared between women who received 17-alpha hydroxyprogesterone caproate or placebo. RESULTS: We included 1094 women; 441 had singleton and 653 had twin gestations. Combining the 2 studies, 616 received 17-alpha hydroxyprogesterone caproate and 478 received placebo. Among singleton and twin pregnancies, rates of gestational diabetes were similar in women receiving 17-alpha hydroxyprogesterone caproate vs placebo (5.8% vs 4.7%; P = .64 and 7.4% vs 7.6%; P = .94, respectively). In the multivariable model, progesterone was not associated with gestational diabetes (adjusted odds ratio, 1.04; 95% confidence interval, 0.62-1.73). CONCLUSION: Weekly administration of 17-alpha hydroxyprogesterone caproate is not associated with higher rates of gestational diabetes in either singleton or twin pregnancies.
Authors: Dwight J Rouse; Steve N Caritis; Alan M Peaceman; Anthony Sciscione; Elizabeth A Thom; Catherine Y Spong; Michael Varner; Fergal Malone; Jay D Iams; Brian M Mercer; John Thorp; Yoram Sorokin; Marshall Carpenter; Julie Lo; Susan Ramin; Margaret Harper; Garland Anderson Journal: N Engl J Med Date: 2007-08-02 Impact factor: 91.245
Authors: Kai J Buhling; Wolfgang Henrich; Elizabeth Starr; Marion Lubke; Silke Bertram; Gerda Siebert; Joachim W Dudenhausen Journal: Arch Gynecol Obstet Date: 2003-04-02 Impact factor: 2.344
Authors: Frédéric Picard; Mitsuhiro Wanatabe; Kristina Schoonjans; John Lydon; Bert W O'Malley; Johan Auwerx Journal: Proc Natl Acad Sci U S A Date: 2002-11-15 Impact factor: 11.205
Authors: K L Margolis; D E Bonds; R J Rodabough; L Tinker; L S Phillips; C Allen; T Bassford; G Burke; J Torrens; B V Howard Journal: Diabetologia Date: 2004-07-14 Impact factor: 10.122
Authors: Andrei Rebarber; Niki B Istwan; Karen Russo-Stieglitz; Jane Cleary-Goldman; Debbie J Rhea; Gary J Stanziano; Daniel H Saltzman Journal: Diabetes Care Date: 2007-06-11 Impact factor: 19.112
Authors: Paul J Meis; Mark Klebanoff; Elizabeth Thom; Mitchell P Dombrowski; Baha Sibai; Atef H Moawad; Catherine Y Spong; John C Hauth; Menachem Miodovnik; Michael W Varner; Kenneth J Leveno; Steve N Caritis; Jay D Iams; Ronald J Wapner; Deborah Conway; Mary J O'Sullivan; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe Journal: N Engl J Med Date: 2003-06-12 Impact factor: 91.245
Authors: Atsushi Goto; Brian H Chen; Kei-Hang K Chan; Cathy Lee; Sarah C Nelson; Andrew Crenshaw; Ebony Bookman; Karen L Margolis; Michèle M Sale; Maggie C Y Ng; Alexander P Reiner; Simin Liu Journal: J Diabetes Date: 2018-04-06 Impact factor: 4.006